Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low to Intermediate-1 MDS”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Testing effectiveness (Phase 2)Ended earlyNCT00699842
What this trial is testing

A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) Patients

Who this might be right for
Myelodysplastic SyndromeMDSLow to Intermediate-1 MDS+1 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 8
Large-scale testing (Phase 3)Active Not RecruitingNCT02598661
What this trial is testing

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndromes
Geron Corporation 289
Testing effectiveness (Phase 2)Study completedNCT01497145
What this trial is testing

A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome

Who this might be right for
MDS
Kyowa Kirin Co., Ltd. 45
Testing effectiveness (Phase 2)Ended earlyNCT00495547
What this trial is testing

SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
PETHEMA Foundation 16
Large-scale testing (Phase 3)Active Not RecruitingNCT00843882
What this trial is testing

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Who this might be right for
AnemiaChronic Myelomonocytic LeukemiaDe Novo Myelodysplastic Syndrome+1 more
National Cancer Institute (NCI) 247
Testing effectiveness (Phase 2)Ended earlyNCT00542828
What this trial is testing

Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome (MDS)
Genzyme, a Sanofi Company 16
Testing effectiveness (Phase 2)Study completedNCT01904682
What this trial is testing

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Who this might be right for
Myelodysplastic Syndromes
Traws Pharma, Inc. 45
Early research (Phase 1)WithdrawnNCT02075034
What this trial is testing

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Study completedNCT03337451
What this trial is testing

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 14
Large-scale testing (Phase 3)Ended earlyNCT00804050
What this trial is testing

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Who this might be right for
Myelodysplastic Syndromes
Fondazione Italiana Sindromi Mielodisplastiche-ETS 184
Testing effectiveness (Phase 2)Study completedNCT01338337
What this trial is testing

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

Who this might be right for
Myelodysplastic Syndrome (MDS)
Asociación Andaluza de Hematología y Hemoterapia 40
Testing effectiveness (Phase 2)Study completedNCT00303472
What this trial is testing

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Who this might be right for
ThrombocytopeniaMDSMyelodysplastic Syndromes+1 more
Amgen 72
Testing effectiveness (Phase 2)Looking for participantsNCT03886662
What this trial is testing

LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic Syndromes
Lixte Biotechnology Holdings, Inc. 47
Testing effectiveness (Phase 2)Study completedNCT02363491
What this trial is testing

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Opsona Therapeutics Ltd. 96
Testing effectiveness (Phase 2)Study completedNCT00700206
What this trial is testing

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome (MDS)
Telik 86
Testing effectiveness (Phase 2)Study completedNCT00418665
What this trial is testing

A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid

Who this might be right for
Myelodysplastic SyndromesThrombocytopenia
Amgen 39
Testing effectiveness (Phase 2)Ended earlyNCT01222195
What this trial is testing

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT03011034
What this trial is testing

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Who this might be right for
Myelodysplastic Syndromes
Janssen Research & Development, LLC 34
Testing effectiveness (Phase 2)Study completedNCT01015352
What this trial is testing

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 98
Large-scale testing (Phase 3)Ended earlyNCT00695396
What this trial is testing

A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Who this might be right for
Myelodysplastic SyndromesAnemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 25
Load More Results